Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Serdexmethylphenidate And Dexmethylphenidate · Azstarys, KP415

Small molecule · developed by Commave Sub

Approved FDA, Mar 2021
1 Registered trials

What is Serdexmethylphenidate And Dexmethylphenidate?

Serdexmethylphenidate is a prodrug of dexmethylphenidate, a central nervous system stimulant. The mode of therapeutic action in ADHD is not known.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Azstarys, KP415, SDX/d-MPH
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Commave Sub
In trials of
ZVRA
FDA status
Approved as Azstarys (March 2, 2021), NDA212994 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of May 11, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03460652 Phase 3 ADHD Completed ZVRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ADHD

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.